Test Code 13ACT Coagulation Factor XIII (13) Activity Assay, Plasma
Ordering Guidance
Coagulation testing is highly complex, often requiring the performance and correlation of factor XIII activity with multiple assays and correlation with clinical information. For that reason, if indicated, consider ordering ALBLD / Bleeding Diathesis Profile, Limited, Plasma.
Specimen Required
Patient Preparation:
1. Fasting: 8 hours, preferred but not required
2. It is best to perform this study pre-plasma transfusion if possible. If patient has been recently transfused, wait at least 48 hours after transfusion before collecting the specimen.
3. Specimen should be collected prior to factor replacement therapy.
Collection Container/Tube: Light-blue top (3.2% sodium citrate)
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL Platelet-poor plasma
Collection Instructions:
1. For complete instructions, see Coagulation Guidelines for Specimen Handling and Processing.
2. Centrifuge, transfer all plasma into a plastic vial, and centrifuge plasma again.
3. Aliquot plasma into a plastic vial, leaving 0.25 mL in the bottom of centrifuged vial.
4. Freeze plasma immediately (no longer than 4 hours after collection) at -20° C or, ideally, -40° C or below.
Additional Information:
1. Double-centrifuged specimen is critical for accurate results.
2. Each coagulation assay requested should have its own vial.
Secondary ID
623415Useful For
Measuring factor XIII activity
Special Instructions
Method Name
Fluorescence-Based Enzyme Activity
Specimen Type
Plasma Na CitSpecimen Minimum Volume
Platelet-poor plasma: 0.5 mL
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Plasma Na Cit | Frozen | 180 days |
Reject Due To
| Gross Hemolysis | Reject |
| Gross Lipemia | Reject |
| Gross Icterus | Reject |
Reference Values
≥55%
Interpretation
Decreased factor XIII (FXIII) activity could reflect acquired conditions (eg, autoimmune conditions [systemic lupus erythematosus, rheumatoid arthritis, malignancy, monoclonal gammopathy of undetermined significance, medication-isoniazid], increased consumption [surgery, disseminated intravascular coagulation/intravascular coagulation and fibrinolysis, inflammatory bowel disease, Henoch-Schonlein purpura, sepsis, thrombosis], decreased synthesis [liver disease, leukemia, medication-valproic acid and tocilizumab]), autoantibodies to FXIII, or a congenital deficiency state.
Normal FXIII activity makes a congenital or acquired FXIII deficiency less likely. Individuals with heterozygous FXIII-A deficiency have FXIII activity between 30% and 70% and are generally considered to be asymptomatic. However, several studies have reported severe bleeding in affected individuals.
Recent transfusion of plasma, cryoprecipitate, or FXIII concentrate will raise FXIII levels and may mask a diagnosis of FXIII deficiency.
Method Description
Factor XIII (FXIII) is activated by thrombin in the presence of calcium. Activated FXIII then cleaves the sidechain carboxamide bond of the assay’s substrate and thereby releases the dark quencher (2,4-dinitrophenyl) linked to the cadaverine spacer. Subsequently, the increase of fluorescence results from the N-terminally attached fluorophore N-methyl-2-aminobenzoic acid. The fluorescent signal is proportional to the FXIII activity in the plasma sample.(Package insert: Technofluor FXIII Activity. Technoclone; 07/15/2020)
Day(s) Performed
Monday through Friday
Report Available
1 to 8 daysSpecimen Retention Time
7 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
CPT Code Information
85290
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| 13ACT | Factor XIII(13) Activity, P | In Process |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 623415 | Factor XIII (13) Activity, P | In Process |
Forms
If not ordering electronically, complete, print, and send an Coagulation Test Request (T753) with the specimen.